Expressão da proteína Bax no tecido mamário normal de mulheres no menacme tratadas com raloxifeno

The actual role of Bax protein as a prognostic biomarker that predicts response to therapy remains unclear. The objective of this study was to evaluate the effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women. Twenty postmenopausal patients with operable stage II, estrogen receptor-positive, infiltrating ductal breast carcinoma were treated with oral raloxifene at a dose of 60 mg/day for a period of 28 days before definitive surgery. Tumor samples were obtained by incisional biopsy at the time of diagnosis and again at the time of definitive surgical treatment. Immunohistochemical evaluation of Bax expression was assessed semiquantitatively based on the fraction of stained tumor cells and intensity of staining. McNemar's test was used to analyze data (P < 0.05). Eleven of the 20 (55%) patients were classified as positive for Bax expression before raloxifene treatment, whereas 9(45%) were classified as positive after raloxifene treatment (P = 0.479). In conclusion, raloxifene did not alter Bax expression significantly in estrogen receptor-positive breast carcinomas of postmenopausal women.

show abstract

The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women

Lopes-Costa

Santos

Silva

2010

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Expressão da proteína Bax no tecido mamário normal de mulheres no menacme tratadas com raloxifeno

Abstract: raloxifene, administered for 22 days in the dose of 60 mg/day, did not alter the expression of Bax protein in the breast normal tissue of premenopausal women.

Cited by 1 publication

References 0 publications

The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women

The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women

Contact Info

Product

Resources

About